Subscribe to this collection to receive daily e-mail notification of new additions

	Title	Author(s)	Issue Date
	EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer Journal:Oncogene	Hui, RinaCampbell, Douglas H.Lee, Christine S.L.McCaul, KieranHorsfall, David J.Musgrove, Elizabeth A.Daly, Roger J.Seshadri, RamSutherland, Robert L.	1997
	Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer Journal:Clinical Cancer Research	Kenny, Frances S.Hui, RinaMusgrove, Elizabeth A.Gee, Julia M.W.Blamey, Roger W.Nicholson, Robert I.Sutherland, Robert L.Robertson, John F.R.	1999
	Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer Journal:Clinical Cancer Research	Hui, RinaCornish, Ann L.McClelland, Richard A.Robertson, John F.R.Blamey, Roger W.Musgrove, Elizabeth A.Nicholson, Robert I.Sutherland, Robert L.	1996
	Cyclins and breast cancer. Journal:Journal of mammary gland biology and neoplasia	Musgrove, E. A.Hui, R.Sweeney, K. J.Watts, C. K.Sutherland, R. L.	1996
	Cyclin-dependent kinases as downstream targets of oestrogen action: Potential prognostic indicators and therapeutic targets Journal:Endocrine-Related Cancer	Sutherland, R. L.Prall, O. W.J.Alle, K. M.Wilcken, N. R.C.Hui, R.Ball, J. R.Sarcevic, B.Henshall, S. M.Musgrove, E. A.Watts, C. K.W.	1997
	Radiotherapy and concurrent chemotherapy for oesophageal carcinoma Journal:Australasian Radiology	HUI, RINABULL, COLIN A.GEBSKI, VALO'ROURKE, IAN	1994
	Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis Journal:Clinical Cancer Research	Seshadri, RamLee, Christine S.L.Hui, RinaMcCaul, KieranHorsfall, David J.Sutherland, Robert L.	1996
	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies Journal:Journal for ImmunoTherapy of Cancer	Schöffski, PatrickTan, Daniel S.W.Martín, MiguelOchoa-De-Olza, MariáSarantopoulos, JohnCarvajal, Richard D.Kyi, ChrisannEsaki, TaitoPrawira, AmyAkerley, WallaceDe Braud, FilippoHui, RinaZhang, TianSoo, Ross A.Maur, MichelaWeickhardt, AndrewKrauss, JürgenDeschler-Baier, BarbaraLau, AllenSamant, Tanay S.Longmire, TylerChowdhury, Niladri RoySabatos-Peyton, Catherine A.Patel, NidhiRamesh, RadhaHu, TiancenCarion, AnaGusenleitner, DanielYerramilli-Rao, PadmajaAskoxylakis, VasileiosKwak, Eunice L.Hong, David S.	2022
	Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres Journal:Cancer Medicine	Brown, Lauren J.da Silva, Ines PiresMoujaber, TaniaGao, BoHui, RinaGurney, HowardCarlino, MatteoNagrial, Adnan	2022
	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer Journal:Journal of Clinical Oncology	Spigel, David R.Faivre-Finn, CorinneGray, Jhanelle E.Vicente, DavidPlanchard, DavidPaz-Ares, LuisVansteenkiste, Johan F.Garassino, Marina C.Hui, RinaQuantin, XavierRimner, AndreasWu, Yi LongÖzgüroǧlu, MustafaLee, Ki H.Kato, TerufumiDe Wit, MaikeKurata, TakayasuReck, MartinCho, Byoung C.Senan, SureshNaidoo, JarushkaMann, HelenNewton, MichaelThiyagarajah, PirunthaAntonia, Scott J.	2022
	Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial Journal:ESMO Open	Senan, S.Özgüroğlu, M.Daniel, D.Villegas, A.Vicente, D.Murakami, S.Hui, R.Faivre-Finn, C.Paz-Ares, L.Wu, Y. L.Mann, H.Dennis, P. A.Antonia, S. J.	2022
	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial Journal:Lung Cancer	Naidoo, JarushkaVansteenkiste, Johan F.Faivre-Finn, CorinneÖzgüroğlu, MustafaMurakami, ShujiHui, RinaQuantin, XavierBroadhurst, HelenNewton, MichaelThiyagarajah, PirunthaAntonia, Scott J.	2022